ADC Therapeutics SA (ADCT)

ADC Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	68.62	69.56	209.91	33.92	0	2.34
Revenue Growth (YoY)	-62.38%	-66.86%	518.89%	-	-	105.26%
Cost of Revenue	4.45	2.53	3.3	1.39	0	0
Gross Profit	64.17	67.03	206.61	32.52	0	2.34
Selling, General & Admin	98.82	105.89	143.49	136.24	77.23	14.2
Research & Development	113.38	127.13	186.46	158	142.03	107.54
Operating Expenses	212.2	233.02	329.95	294.24	219.26	121.74
Operating Income	-148.03	-165.99	-123.34	-261.72	-219.26	-119.4
Interest Expense / Income	48.97	46.33	36.73	18.34	4.93	0.16
Other Expense / Income	-9.3	-11.36	-3.17	-28.56	21.77	-3.65
Pretax Income	-187.7	-200.95	-156.9	-251.51	-245.96	-115.9
Income Tax	39.53	39.11	0.23	-21.48	0.33	0.58
Net Income	-227.23	-240.05	-157.13	-230.03	-246.29	-116.48
Shares Outstanding (Basic)	83	82	78	77	71	67
Shares Outstanding (Diluted)	-	82	78	-	-	-
Shares Change	2.16%	4.55%	1.84%	8.21%	6.04%	-
EPS (Basic)	-2.77	-2.94	-2.01	-3.00	-3.77	-2.36
EPS (Diluted)	-2.77	-2.94	-2.01	-3.00	-3.77	-2.36
Free Cash Flow	-156.85	-121.9	-139	-230.93	-168.85	-122.8
Free Cash Flow Per Share	-1.90	-1.49	-1.78	-3.01	-2.38	-1.84
Gross Margin	93.52%	96.36%	98.43%	95.89%	-	100.00%
Operating Margin	-215.72%	-238.63%	-58.76%	-771.65%	-	-5102.52%
Profit Margin	-331.15%	-345.11%	-74.86%	-678.20%	-	-4977.95%
Free Cash Flow Margin	-228.58%	-175.25%	-66.22%	-680.85%	-	-5247.74%
EBITDA	-135.32	-151.36	-117.78	-230.54	-239.07	-114.1
EBITDA Margin	-197.20%	-217.60%	-56.11%	-679.70%	-	-4876.07%
Depreciation & Amortization	3.42	3.27	2.39	2.63	1.97	1.65
EBIT	-138.73	-154.62	-120.17	-233.17	-241.04	-115.75
EBIT Margin	-202.18%	-222.29%	-57.25%	-687.46%	-	-4946.41%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).